For a long time peritoneal carcinomatosis has been considered as a pathological condition that cannot be treated surgically and does not respond satisfactorily to chemotherapy. Due to the specificity of this kind of malignancy, up until a few years ago, it was considered "impossible" to intervene surgically and recovery was considered impossible. Another obstacle to the treatment seems to have been attributed to the inability of some drugs to accumulate at the peritoneal level. The peritoneum is one of the most common areas of metastasis, after therapeutic surgeries, for the removal of intraventricular tumors.
Today, the therapeutic treatment of peritoneal carcinomatosis is feasible through the combination of surgical intervention and hyperthermic intraperitoneal chemotherapy.
The evolution and availability of various treatments and innovative methods in surgery and pharmaceuticals allow us to tream peritoneal carcinomatosis effectively. It is the best possible therapeutic approach, combining surgical intervention and hyperthermic intraperitoneal chemotherapy in a therapeutic scheme that is organized into two stages: firstly, the surgical removal of the disease and then the peritoneal cavity is "lavaged" with a high concentration of chemotherapy drugs to fight the circulating free cancer cells. Surgical intervention and hyperthermic intraperitoneal chemotherapy are two separate but equally important stages of the same therapeutic scheme with successful results. The two stages must be carried out one immediately after the other, in order to achieve maximum therapeutic efficiency. In reality, even if one week passes between stages, hyperthermic intraperitoneal chemotherapy becomes ineffective since the free cancer cells get "trapped" in a very short time inside newly formed tissue, where they are absorbed, hidden and are, generally protected.